Lilly's Lechleiter eliminates manufacturing posts

Share this article:
Lilly CEO John Lechleiter
Lilly CEO John Lechleiter
In his first major move as CEO, Eli Lilly's John Lechleiter today announced plans to cut 500 manufacturing jobs at sites near the company's Indianapolis headquarters.

The manufacturing sites focused on production of ingredients for insulin products Humulin and Humalog and osteoporosis treatment Forteo. While most of the cuts are planned for manufacturing, some will come from R&D, Lilly said.

“For several years we have focused on strategic efforts to lower costs, increase flexibility and improve productivity across the business,” Lechleiter said in a statement. “This strategy calls for reducing investments in some areas while increasing investments in others, and the streamlining decisions announced today are an example of this.”

Lechlieter stepped into the CEO role at Lilly on April 1, replacing Sidney Taurel who retired at the end of March.

Lilly has cut its global employment, mostly through attrition, by about 12% since the middle of 2004 and now has approximately 5,500 workers.

The job cuts follow Lilly's decision last month to scrap development of its inhaled insulin device dubbed AIR. 

A late-stage trial of AIR was slated to wrap in time for NDA submission of the product in 2009.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.